Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Accured Expenses for 18 years, with the latest figure at $222.5 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 33.55% year-over-year to $222.5 million in Q2 2026; TTM through Jun 2026 was $226.8 million, a 247.85% increase from a year earlier, with the FY2025 full-year figure at $148.5 million, down 30.25% from the prior year.
• Change in Accured Expenses was $222.5 million for Q2 2026 at Vertex Pharmaceuticals, up from $70.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $485.5 million in Q2 2022, with the low at -$437.8 million in Q4 2022.
• Average Change in Accured Expenses over 5 years is $90.4 million, with a median of $167.4 million recorded in 2024.
• The largest YoY upside for Change in Accured Expenses was 1167.03% in 2022 against a maximum downside of 955.08% in 2022.
• Over 5 years, Change in Accured Expenses stood at -$437.8 million in 2022, then advanced by 18.52% to -$356.7 million in 2023, then increased by 10.26% to -$320.1 million in 2024, then retreated by 24.68% to -$399.1 million in 2025, then surged by 155.75% to $222.5 million in 2026.
• The last three Change in Accured Expenses figures came in at $222.5 million (Q2 2026), $70.5 million (Q1 2026), and -$399.1 million (Q4 2025), per Business Quant data.